BioXcel Therapeutics, Inc. news

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 1:45 p.m. Eastern Time. Management will discuss the Co

• SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use
• Top-line pivotal data expected in 1H 2023
• Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. ^1-4

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 2:30 p.m. Eastern Time. Management will discuss

• Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment
• Over 142 million opioid prescriptions dispensed in the U.S. in 20201
• More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizi

• Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023
• Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study

• OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need
• New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises
• Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in Phase 2 clinical trials

BioXcel Th

• First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder¹
• IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studies¹
• Up to 25 million agitation episodes for these two patient populations in the U.S. annually²

• BXCL701 plus KEYTRUDA (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts
• Company plans to continue evaluation of BXCL701 combination as potentially differentiated approach for mCRPC patients
• Results support BXCL701’s potential to extend checkpoint inhibitor therapy into cold tumor settings

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharm